Literature DB >> 6334608

Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man.

P J Pentikäinen, O Tokola, E Alhava, A Penttilä.   

Abstract

To study its pharmacokinetics and especially microCi/100 mg was infused i.v. in 8 patients with a T-tube inserted in the common bile duct at choledocholithotomy 7-10 days prior to the study. Bile was collected in fractions by continuous suction over a 24 h period. Blood samples were taken and urine collected up to 48 h after the dose. Tolfenamic acid and its metabolites were separated by TLC and were quantitated by liquid scintillation counting. The pharmacokinetics of tolfenamic acid could be described by a two compartment open model with V1 of 3.67 +/- 0.681 and VSS of 8.0 +/- 1.01. The total plasma clearance of tolfenamic acid averaged 106 +/- 8 ml/min and t1/2 beta was 1.38 +/- 0.32 h. A three compartment open model was required to describe the kinetics of total 14C. The plasma clearance of total 14C was 15.4 +/- 3.9 ml/min and its terminal half life averaged 19.0 +/- 4.1 h. The long half-life was caused by the slow elimination of tolfenamic acid metabolites. Four metabolites were measured in plasma and bile. The principal metabolites in bile were glucuronide/sulphate conjugates of hydroxylated derivatives of tolfenamic acid. The recovery of tolfenamic acid in bile was 1.1 +/- 0.3% of the dose, whereas the recovery of total 14C was 18.6 +/- 4.9%. The biliary clearances of tolfenamic acid and total 14C were 1.2 +/- 0.3 and 5.0 +/- 2.1 ml/min, respectively. Thus, biliary excretion plays a considerable part in the pharmacokinetics of tolfenamic acid.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6334608     DOI: 10.1007/bf00542174

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man.

Authors:  K C Kwan; G O Breault; E R Umbenhauer; F G McMahon; D E Duggan
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

2.  Disposition and oxidative metabolism of phenylbutazone in man.

Authors:  J Aarbakke; O M Bakke; E J Milde; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

3.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

4.  Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Authors:  D E Duggan; K F Hooke; R M Noll; K C Kwan
Journal:  Biochem Pharmacol       Date:  1975-10-01       Impact factor: 5.858

5.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

6.  Tolfenamic acid. Detection and structure of urinary metabolites.

Authors:  S B Pedersen; B Alhede; O Buchardt; J Møller; K Bock
Journal:  Arzneimittelforschung       Date:  1981

7.  Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates.

Authors:  R G Khalifah; C E Hignite; P J Pentikäinen; A Penttilä; P J Neuvonen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

8.  Indomethacin intravenously--a new way for effective relief of biliary pain: a double-blind study in man.

Authors:  E Thornell; R Jansson; J Svanvik
Journal:  Surgery       Date:  1981-09       Impact factor: 3.982

Review 9.  Biliary excretion of drugs in man.

Authors:  D E Rollins; C D Klaassen
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

10.  Inhibition of prostaglandin synthesis as a treatment for biliary pain.

Authors:  E Thornell; R Jansson; J G Kral; J Svanvik
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321

View more
  4 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid.

Authors:  R T Foster; F Jamali; A S Russell
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver.

Authors:  J Stenderup; J Eriksen; S B Pedersen; L V Christiansen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Mechanistic approaches to volume of distribution predictions: understanding the processes.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.